{"id":942349,"date":"2026-03-05T12:04:19","date_gmt":"2026-03-05T17:04:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/"},"modified":"2026-03-05T12:04:19","modified_gmt":"2026-03-05T17:04:19","slug":"important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/","title":{"rendered":"Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf"},"content":{"rendered":"
\n

PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) — <\/p>\n

\n
\n Corcept Therapeutics, Inc. (NASDAQ: CORT):<\/u>
\n <\/strong>\n <\/p>\n

\n WHAT IS HAPPENING?<\/strong> Grabar Law Office is investigating claims on behalf of shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

\n If you purchased Corcept (NASDAQ: CORT)<\/strong>
\n shares prior to <\/strong>
\n October 31, 2024<\/strong>
\n , <\/strong>
\n you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong>\u00a0\u00a0 Please<\/strong> visit <\/strong>https:\/\/grabarlaw.com\/the-latest\/corcept-shareholder-investigation\/<\/strong><\/a>, contact Joshua Grabar at <\/strong>jgrabar@grabarlaw.com<\/strong><\/a>, <\/strong>or call us at 267-507-6085. <\/strong><\/p>\n

\n WHY?<\/strong> According to a recently filed federal securities fraud class action lawsuit, Corcept Therapeutics. Inc. (NASDAQ: CORT), through certain of its officers falsely represented that the key clinical trials supporting the use of relacorilant as treatment for patients with hypercortisolism were \u201cpowerful support\u201d for the New Drug Application (\u201cNDA\u201d) that Corcept submitted to the U.S. Food and Drug Administration (\u201cFDA\u201d) for this indication. Defendants also stated that they had communicated with the FDA about this NDA and were confident in submitting the NDA, foreseeing no impediments to approval. Defendants repeatedly told investors that \u201crelacorilant is approaching approval.\u201d<\/p>\n

In time, it was revealed that Defendants\u2019 representations that the relacorilant NDA was supported by powerful evidence, that it was approaching approval, and that they had no concerns about the FDA\u2019s review were false. In truth, the FDA had repeatedly raised concerns about the adequacy of the clinical evidence supporting the NDA and, as a result, there was a known material risk that Corcept\u2019s relacorilant NDA would not be approved.<\/p>\n

The truth emerged on December 31, 2025, when Corcept revealed that the FDA had issued a Complete Response Letter (\u201cCRL\u201d) regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had \u201cconcluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.\u201d The press release quoted Defendant Belanoff as stating that \u201c[w]e are surprised and disappointed by this outcome.\u201d<\/p>\n

On January 30, 2026, the FDA published a redacted copy of the CRL. The CRL detailed the FDA\u2019s concerns with the relacorilant NDA, including concerns that the clinical studies that were submitted as part of the NDA were not sufficient evidence of relacorilant\u2019s efficacy for the proposed indication. The CRL also noted that, during pre-submission meetings, the FDA informed Corcept \u201con several occasions\u201d of its \u201cconcerns about the adequacy of the clinical development program,\u201d and had warned the Company \u201cto expect significant review issues,\u201d if it submitted the application.<\/p>\n

\n WHAT CAN YOU DO NOW?<\/strong>
\n If you purchased <\/strong>
\n Corcept Therapeutics. Inc. (NASDAQ: CORT) <\/strong>
\n shares prior to <\/strong>
\n October 31, 2024, <\/strong>
\n you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/corcept-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong>\u00a0\u00a0 #CORT $CORT<\/p>\n

\n
\n Kyndryl Holdings, Inc. (NYSE: KD):<\/u>
\n <\/strong>\n <\/p>\n

\n WHAT IS HAPPENING?<\/strong> Grabar Law Office is investigating claims on behalf of shareholders of Kyndryl Holdings, Inc. (NYSE: KD). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

\n If you purchased Kyndryl Holdings (NYSE: KD) shares prior to <\/strong>
\n August 7, 2024<\/strong>
\n , <\/strong>
\n you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong>\u00a0\u00a0 Please<\/strong> visit <\/strong>https:\/\/grabarlaw.com\/the-latest\/kyndryl-shareholder-investigation\/<\/strong><\/a>, contact Joshua Grabar at <\/strong>jgrabar@grabarlaw.com<\/strong><\/a>, <\/strong>or call 267-507-6085 to learn more. <\/strong><\/p>\n

\n WHY?<\/strong> According to a recently filed federal securities fraud class action lawsuit, on February 9, 2026, Kyndryl Holdings announced that it was unable to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025, that the\u00a0Securities and Exchange Commission was investigating<\/em><\/strong>\u00a0the Company’s cash management practices and disclosures, that the Audit Committee of the Board of Directors was reviewing those issues internally, that the Company anticipated reporting\u00a0material weaknesses in internal controls<\/em><\/strong>\u00a0with respect to information and communication, as well as tone at the top.<\/p>\n

\n WHAT CAN YOU DO NOW?<\/strong>
\n If you purchased Kyndryl Holdings (NYSE: KD) shares prior to <\/strong>
\n August 7, 2024, <\/strong>
\n you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/kyndryl-shareholder-investigation\/<\/strong>
\n <\/a>
\n , <\/strong>
\n contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong>\u00a0\u00a0<\/p>\n

#Kyndryl #KD $KD<\/p>\n

\n
\n Molina Healthcare, Inc. <\/u>
\n <\/strong>
\n
\n (NYSE: MOH)<\/u>
\n <\/strong>
\n :<\/strong>\n <\/p>\n

\n WHAT IS HAPPENING?<\/strong> Grabar Law Office is investigating claims on behalf of shareholders of Molina Healthcare, Inc. (NYSE: MOH). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

\n If you purchased <\/strong>
\n Molina Healthcare, Inc. <\/strong>
\n (NYSE: MOH)<\/strong>
\n , <\/strong>
\n shares prior to <\/strong>
\n February 5, 2025<\/strong>
\n and still hold shares today, <\/strong>
\n you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/molina-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085 to learn more. <\/strong>\n <\/p>\n

\n WHY?<\/strong> As alleged in an underlying securities fraud class action complaint, Molina Healthcare, Inc. (NYSE: MOH), through certain of its officers, failed to disclose: (1) material, adverse facts concerning Molina Healthcare’s “medical cost trend assumptions”; (2) that Molina Healthcare was experiencing a “dislocation between premium rates and medical cost trend”; (3) that Molina Healthcare’s near term growth was dependent on a lack of “utilization of behavioral health, pharmacy, and inpatient and outpatient services”; and (4) as a result, Molina Healthcare’s financial guidance for fiscal year 2025 was substantially likely to be cut.<\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong>
\n If you purchased <\/strong>
\n Molina Healthcare, Inc. <\/strong>
\n (NYSE: MOH)<\/strong>
\n , <\/strong>
\n shares prior to <\/strong>
\n February 5, 2025<\/strong>
\n and still hold shares today, <\/strong>
\n you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/molina-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong>\u00a0\u00a0 $MOH #Molina #MOH<\/p>\n

\n
\n Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY):<\/u>
\n <\/strong>\n <\/p>\n

\n WHAT IS HAPPENING?<\/strong> Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

\n If you purchased <\/strong>
\n Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY) <\/strong>
\n shares prior to <\/strong>
\n March 29, 2024,<\/strong>
\n and still hold shares today, <\/strong>
\n you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/unicycive-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085 to learn more. <\/strong>\n <\/p>\n

\n WHY? <\/strong>As alleged in a recently filed federal securities fraud class action complaint, Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY), through certain of its officers, made false statements and\/or concealed that: (i) Unicycive’s readiness and ability to satisfy the FDA’s manufacturing compliance requirements was overstated; (ii) the oxylanthanum carbonate new drug application’s regulatory prospects were likewise overstated; and (iii) as a result, defendants’ public statements were materially false and misleading when made.<\/p>\n

\n WHAT CAN YOU DO NOW?<\/strong>
\n If you purchased <\/strong>
\n Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY), <\/strong>
\n shares prior to <\/strong>
\n March 29, 2024,<\/strong>
\n and still hold shares today, <\/strong>
\n you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/unicycive-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. <\/strong>$UNCY #Unicycive #UNCY<\/p>\n

\n Attorney Advertising Disclaimer<\/a>\n <\/p>\n

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: \u00a0267-507-6085
Email: jgrabar@grabarlaw.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) — Corcept Therapeutics, Inc. (NASDAQ: CORT): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you purchased Corcept (NASDAQ: CORT) shares prior to October 31, 2024 , you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.\u00a0\u00a0 Please visit https:\/\/grabarlaw.com\/the-latest\/corcept-shareholder-investigation\/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. WHY? According to a recently filed federal securities fraud class action lawsuit, Corcept Therapeutics. Inc. (NASDAQ: CORT), through certain of its … <\/p>\n

Continue reading “Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942349","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImportant Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) — Corcept Therapeutics, Inc. (NASDAQ: CORT): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you purchased Corcept (NASDAQ: CORT) shares prior to October 31, 2024 , you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.\u00a0\u00a0 Please visit https:\/\/grabarlaw.com\/the-latest\/corcept-shareholder-investigation\/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. WHY? According to a recently filed federal securities fraud class action lawsuit, Corcept Therapeutics. Inc. (NASDAQ: CORT), through certain of its … Continue reading "Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T17:04:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjU0NCM3NDY5NjQzIzIyMDEyNzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf\",\"datePublished\":\"2026-03-05T17:04:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\\\/\"},\"wordCount\":1321,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjU0NCM3NDY5NjQzIzIyMDEyNzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\\\/\",\"name\":\"Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjU0NCM3NDY5NjQzIzIyMDEyNzA=\",\"datePublished\":\"2026-03-05T17:04:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjU0NCM3NDY5NjQzIzIyMDEyNzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjU0NCM3NDY5NjQzIzIyMDEyNzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/","og_locale":"en_US","og_type":"article","og_title":"Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk","og_description":"PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) — Corcept Therapeutics, Inc. (NASDAQ: CORT): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you purchased Corcept (NASDAQ: CORT) shares prior to October 31, 2024 , you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.\u00a0\u00a0 Please visit https:\/\/grabarlaw.com\/the-latest\/corcept-shareholder-investigation\/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. WHY? According to a recently filed federal securities fraud class action lawsuit, Corcept Therapeutics. Inc. (NASDAQ: CORT), through certain of its … Continue reading \"Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-05T17:04:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjU0NCM3NDY5NjQzIzIyMDEyNzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf","datePublished":"2026-03-05T17:04:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/"},"wordCount":1321,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjU0NCM3NDY5NjQzIzIyMDEyNzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/","name":"Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjU0NCM3NDY5NjQzIzIyMDEyNzA=","datePublished":"2026-03-05T17:04:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjU0NCM3NDY5NjQzIzIyMDEyNzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjU0NCM3NDY5NjQzIzIyMDEyNzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-corcept-therapeutics-inc-nasdaq-cort-kyndryl-holdings-nyse-kd-molina-healthcare-inc-nyse-moh-and-unicycive-therapeutics-inc-nasdaq\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc.\u00a0(NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942349"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942349\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}